Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?-Reference-Cited by-同舟云学术

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

Published:2017-02-27 Issue:2 Volume:12 Page:e0172341
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Taguchi Satoru,Buti Sebastiano,Fukuhara Hiroshi,Otsuka Masafumi,Bersanelli Melissa,Morikawa Teppei,Miyazaki Hideyo,Nakagawa Tohru,Fujimura Tetsuya,Kume Haruki,Igawa Yasuhiko,Homma Yukio

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference26 articles.

1. Renal-cell carcinoma;HT Cohen;N Engl J Med,2005

2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) Kidney Cancer Version 2.2014;RJ Motzer,2014

3. Adjuvant therapy of renal cell carcinoma;TA Yap;Clin Genitourin Cancer,2006

4. Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma;MC Smaldone;Hematol Oncol Clin North Am,2011

5. Systemic adjuvant therapies in renal cell carcinoma;S Buti;Oncol Rev,2012

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT;Health Technology Assessment;2024-08

2. Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments;Clinical Medicine Insights: Oncology;2024-01

3. Adjuvant therapy in renal cell carcinoma: is resection still solely enough?;Future Oncology;2021-02

4. Ameliorative potential of sitagliptin and/or resveratrol on experimentally-induced clear cell renal cell carcinoma;Biomedicine & Pharmacotherapy;2018-01

5. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population;Annals of Oncology;2017-11